Castor Establishes Advisory Board of Industry Leaders to Maximize the Impact of its Clinical Data Platform

Industry veterans including Craig Lipset will support Castor’s vision to advance the future of clinical research Amsterdam, Netherlands and Hoboken, New Jersey:  November 18, 2019: Castor, a health-tech company that aims to leverage machine readable data to increase clinical trial efficiency, today announces the formation of an independent Advisory Board. Castor’s Electronic Data Capture (EDC) […]

Theragnostics strengthens leadership team with two key appointments

Chris Sterling appointed as Non-Executive Director & Radiopharmaceutical drug development expert Dr Daniel Stevens joins as Chief Medical Officer LONDON, UK, 14 November 2019 – Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces two strategic hires to its leadership team with the appointment of Dr Daniel Stevens […]

Calliditas Interim Report Q3, 2019

Positive Regulatory Outcome – Enhanced study design “This third quarter of 2019 saw us move steadily towards full recruitment of the NefIgArd study, despite a somewhat slower pace during the summer months. We can now see the finish line and we hope that the next couple of months develop as planned so that we can […]

F2G Receives US FDA Breakthrough Therapy Designation for Olorofim

In Phase 2b development for the treatment of life-threatening fungal infections First antifungal agent to receive Breakthrough Therapy designation MANCHESTER, UK / VIENNA, Austria – November 11, 2019 – F2G Ltd, a UK- and Austria-based biotech company developing novel therapies for life-threatening systemic fungal infections, announced today that the US Food and Drug Administration (FDA) has […]

Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor

CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ — Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma. Under the agreement, Artios has exclusive rights to research, develop, manufacture and commercialize […]

© Optimum Strategic Communications.